乙型肝炎：治疗现状与未来疗法。
Hepatitis B: Current Status of Therapy and Future Therapies.
机构信息
MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC, USA; Nazih Zuhdi Transplant Institute, INTEGRIS Baptist Medical Center, Oklahoma City, OK, USA.
MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC, USA.
出版信息
Gastroenterol Clin North Am. 2020 Jun;49(2):215-238. doi: 10.1016/j.gtc.2020.01.003. Epub 2020 Mar 29.
Abstract
Despite the availability of a protective vaccine for over 3 decades, the number of persons with chronic hepatitis B virus (HBV) infection remains high. These persons are at risk for cirrhosis and hepatocellular carcinoma. Current treatment is effective at inhibiting viral replication and reducing complications of chronic HBV infection, but is not curative. There is a need for novel, finite therapy that can cure chronic HBV infection. Several agents are in early-phase development and can be broadly viewed as agents that target the virus directly or indirectly or the host immune response. This article highlights key developments in antiviral/immunomodulatory therapy, the rationale for these approaches, and possible therapeutic regimens.
摘要
尽管已有 30 多年的保护疫苗，但慢性乙型肝炎病毒 (HBV) 感染者的人数仍然居高不下。这些人有发展为肝硬化和肝细胞癌的风险。目前的治疗方法可以有效抑制病毒复制，减少慢性 HBV 感染的并发症，但无法治愈。需要新的、有限的治疗方法来治愈慢性 HBV 感染。有几种药物处于早期开发阶段，可以大致分为直接或间接针对病毒或宿主免疫反应的药物。本文重点介绍抗病毒/免疫调节治疗方面的重要进展，这些方法的原理以及可能的治疗方案。
相似文献
1
Hepatitis B: Current Status of Therapy and Future Therapies.乙型肝炎：治疗现状与未来疗法。
Gastroenterol Clin North Am. 2020 Jun;49(2):215-238. doi: 10.1016/j.gtc.2020.01.003. Epub 2020 Mar 29.
2
Towards the elimination of hepatitis B and hepatocellular carcinoma.迈向消除乙型肝炎和肝细胞癌
S Afr Med J. 2018 Aug 8;108(8b):13-16. doi: 10.7196/SAMJ.2018.v108i8b.13496.
3
Hepatitis B virus vaccine for patients with hepatitis C virus infection.用于丙型肝炎病毒感染患者的乙型肝炎病毒疫苗。
Infection. 2000 Nov-Dec;28(6):341-5. doi: 10.1007/s150100070002.
4
The current state of the prevention of HBV infection, the carrier state and hepatocellular carcinoma.
Res Virol. 1997 Mar-Apr;148(2):91-4. doi: 10.1016/s0923-2516(97)89890-1.
5
Impact of hepatitis B therapy on the long-term outcome of liver disease.乙型肝炎治疗对肝脏疾病长期转归的影响。
Liver Int. 2011 Jan;31 Suppl 1:117-21. doi: 10.1111/j.1478-3231.2010.02388.x.
6
Interferon Treatment for Hepatitis B.干扰素治疗乙型肝炎。
Clin Liver Dis. 2016 Nov;20(4):645-665. doi: 10.1016/j.cld.2016.06.002. Epub 2016 Aug 8.
7
NIH consensus development statement on management of hepatitis B.美国国立卫生研究院关于乙型肝炎管理的共识发展声明。
NIH Consens State Sci Statements. 2008;25(2):1-29.
8
Hepatitis D: A Review.肝炎 D：综述。
JAMA. 2023 Dec 26;330(24):2376-2387. doi: 10.1001/jama.2023.23242.
9
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?HBV 抗病毒治疗后的纤维化消退。肝硬化可逆吗？
Liver Int. 2014 Feb;34 Suppl 1:85-90. doi: 10.1111/liv.12395.
10
Review article: the prevention of hepatitis B-related hepatocellular carcinoma.综述文章：乙型肝炎相关肝细胞癌的预防。
Aliment Pharmacol Ther. 2018 Jul;48(1):5-14. doi: 10.1111/apt.14683. Epub 2018 May 3.
引用本文的文献
1
Identifying Expert Opinions on the Challenges and Barriers Faced in Implementing Iraq's National Plan for Controlling Hepatitis B.识别关于伊拉克控制乙型肝炎国家计划实施过程中所面临挑战和障碍的专家意见。
Cureus. 2024 Jun 21;16(6):e62814. doi: 10.7759/cureus.62814. eCollection 2024 Jun.
2
HBeAg induces neutrophils activation impairing NK cells function in patients with chronic hepatitis B.HBeAg 诱导中性粒细胞活化，损害慢性乙型肝炎患者 NK 细胞功能。
Hepatol Int. 2024 Aug;18(4):1122-1134. doi: 10.1007/s12072-024-10689-z. Epub 2024 Jun 3.
3
New Treatment Options in Chronic Hepatitis B: How Close Are We to Cure?慢性乙型肝炎的新治疗选择：我们离治愈还有多远？
Infect Dis Clin Microbiol. 2023 Dec 29;5(4):267-280. doi: 10.36519/idcm.2023.265. eCollection 2023 Dec.
4
Prevention in Hepatology.肝病学中的预防
J Pers Med. 2024 Jan 23;14(2):132. doi: 10.3390/jpm14020132.
5
Racial Disparities in Treatment Initiation and Outcomes of Chronic Hepatitis B Virus Infection in North America.北美慢性乙型肝炎病毒感染治疗启动和结局的种族差异。
JAMA Netw Open. 2023 Apr 3;6(4):e237018. doi: 10.1001/jamanetworkopen.2023.7018.
6
Release of hepatitis B virions is positively regulated by glucose-regulated protein 78 through direct interaction with preS1.乙型肝炎病毒粒子的释放是通过葡萄糖调节蛋白 78 与 preS1 的直接相互作用而被正向调节的。
J Med Virol. 2023 Jan;95(1):e28271. doi: 10.1002/jmv.28271.
7
Development of Therapeutic Vaccine for Chronic Hepatitis B: Concept, Cellular and Molecular Events, Design, Limitation, and Future Projection.慢性乙型肝炎治疗性疫苗的研发：概念、细胞与分子事件、设计、局限性及未来展望
Vaccines (Basel). 2022 Sep 30;10(10):1644. doi: 10.3390/vaccines10101644.
8
SEB genotyping: SmartAmp-Eprimer binary code genotyping for complex, highly variable targets applied to HBV.SEB 基因分型：适用于 HBV 的复杂、高度多变目标的 SmartAmp-Eprimer 二进制代码基因分型。
BMC Infect Dis. 2022 Jun 3;22(1):516. doi: 10.1186/s12879-022-07458-4.
9
Association of Nucleostemin Polymorphisms with Chronic Hepatitis B Virus Infection in Chinese Han Population.核干细胞多态性与中国汉族人群慢性乙型肝炎病毒感染的关联。
Genet Test Mol Biomarkers. 2022 May;26(5):255-262. doi: 10.1089/gtmb.2021.0181. Epub 2022 May 16.
10
PreS/2-21-Guided siRNA Nanoparticles Target to Inhibit Hepatitis B Virus Infection and Replication.PreS/2-21 导向的 siRNA 纳米颗粒靶向抑制乙型肝炎病毒感染和复制。
Front Immunol. 2022 Apr 29;13:856463. doi: 10.3389/fimmu.2022.856463. eCollection 2022.
本文引用的文献
1
Disease Pathways and Mechanisms of Potential Drug Targets.疾病途径与潜在药物靶点的机制
Clin Liver Dis (Hoboken). 2018 Aug 22;12(1):12-18. doi: 10.1002/cld.735. eCollection 2018 Jul.
2
A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects.一项随机、双盲、安慰剂对照、首次人体研究，旨在评估 GSK3389404 在健康受试者中单次和多次递增剂量的安全性、耐受性和药代动力学。
Clin Pharmacol Drug Dev. 2019 Aug;8(6):790-801. doi: 10.1002/cpdd.670. Epub 2019 Mar 12.
3
Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection.慢性乙型肝炎病毒感染患者中衣壳组装调节剂 NVR 3-778 的抗病毒活性、安全性和药代动力学。
Gastroenterology. 2019 Apr;156(5):1392-1403.e7. doi: 10.1053/j.gastro.2018.12.023. Epub 2019 Jan 6.
4
Pevonedistat, a Neuronal Precursor Cell-Expressed Developmentally Down-Regulated Protein 8-Activating Enzyme Inhibitor, Is a Potent Inhibitor of Hepatitis B Virus.培维酮司他，一种神经元前体细胞表达的发育下调蛋白 8 激活酶抑制剂，是一种有效的乙型肝炎病毒抑制剂。
Hepatology. 2019 May;69(5):1903-1915. doi: 10.1002/hep.30491. Epub 2019 Mar 13.
5
Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection.马来酸贝昔福韦酯对比富马酸替诺福韦二吡呋酯治疗慢性乙型肝炎病毒感染的疗效和安全性。
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1850-1859.e4. doi: 10.1016/j.cgh.2018.11.001. Epub 2018 Nov 15.
6
ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection.ARB-1740，一种用于慢性乙型肝炎感染的RNA干扰疗法。
ACS Infect Dis. 2019 May 10;5(5):725-737. doi: 10.1021/acsinfecdis.8b00191. Epub 2018 Nov 19.
7
HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.HBsAg 血清学清除在核苷（酸）类似物实现完全病毒抑制后进一步降低肝细胞癌风险。
J Hepatol. 2019 Mar;70(3):361-370. doi: 10.1016/j.jhep.2018.10.014. Epub 2018 Oct 25.
8
Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection.靶向固有和适应性免疫应答以治愈慢性乙型肝炎病毒感染。
Gastroenterology. 2019 Jan;156(2):325-337. doi: 10.1053/j.gastro.2018.10.032. Epub 2018 Oct 24.
9
Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection.抗PD-L1疗法在土拨鼠乙肝病毒感染模型中的安全性和有效性
PLoS One. 2018 Feb 14;13(2):e0190058. doi: 10.1371/journal.pone.0190058. eCollection 2018.
10
Immunotherapy for Chronic Hepatitis B Virus Infection.慢性乙型肝炎病毒感染的免疫治疗。
Gut Liver. 2018 Sep 15;12(5):497-507. doi: 10.5009/gnl17233.
Zotero 插件